Saturday 17 October 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,125.0%, EPS fell 66.7% and free cash flow fell 67.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
59.79
2.07
−3.35%
Follow CGON
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 25.77 | 14.80 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 50.23 | 46.01 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 61 | 61 | 113 | 142 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | 0.03 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 0 | 1 | 4 | ||||
| Gross margin, % | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | (15.02) | |||||
| EBT | — | — | — | — | — | — | (35) | (49) | (88) | (161) | |||||
| EBT margin, % | — | — | — | — | — | — | (18,556.54) | (23,826.96) | (7,729.50) | (3,985.02) | |||||
| Net income | — | — | — | — | — | — | (35) | (49) | (88) | (161) | |||||
| Depreciation | — | — | — | — | — | — | 0 | (3) | (5) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.05 | 0.05 | 0.02 | 0.05 | ||||
| Earnings | — | — | — | — | — | — | (9.47) | (15.65) | (1.41) | (2.08) | |||||
| Cash flow | — | — | — | — | — | — | (7.97) | (10.55) | (1.26) | (1.71) | |||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (7.97) | (10.55) | (1.26) | (1.71) | |||||
| Book value | — | — | — | — | — | — | (20.77) | (28.42) | 11.73 | 9.74 | |||||
| Shares, m | — | — | — | — | — | — | 4 | 4 | 62 | 77 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | 1,573.67 | 713.89 | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 2.44 | 4.26 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 935.83 | 551.48 | |||||
| EV/FCF | — | — | — | — | — | — | 0.25 | 0.25 | (13.50) | (18.72) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (30) | (46) | (79) | (132) | ||||
| Capex | — | — | — | — | — | — | 0 | — | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (30) | (46) | (79) | (132) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 132 | 180 | 733 | 729 | ||||
| Total debt | — | — | — | — | — | — | 15 | — | — | 3 | |||||
| Net debt | — | — | — | — | — | — | (128) | (188) | (742) | (739) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (78) | (123) | 733 | 753 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (39.07) | (18.45) | (20.82) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (886.69) | |||||
| ROE | — | — | — | — | — | — | 0.00 | 67.53 | (28.85) | (21.67) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
CG Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 29.5× | 54.7× | +33.73% (above 0%: growing) | +868.00% (above 0%: growing) | +35.53% (above 0%: growing) | 94.95% | 13.49% | Compare |
| IMVT Immunovant, Inc. | $5.7B | — (loss-making) | — | — | n/m | −5.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KOD Kodiak Sciences Inc. | $5.5B | — (loss-making) | — | — | n/m | −33.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGON CG Oncology, Inc. | $5.5B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.4B | — (loss-making) | — (loss-making) | +37.92% (above 0%: growing) | n/m | −681.46% (below 0%: shrinking) | 82.78% | (24.14%) | Compare |
| ERAS Erasca, Inc. | $5.2B | — (loss-making) | — | — | n/m | −4.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| COGT Cogent Biosciences, Inc. | $5.1B | — (loss-making) | — (loss-making) | −69.41% (below 0%: shrinking) | n/m | −42.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTCT PTC Therapeutics, Inc. | $5.1B | — (loss-making) | 110× | +101.55% (above 0%: growing) | n/m | +295.69% (above 0%: growing) | 94.47% | 41.32% | Compare |
| CRSP CRISPR Therapeutics AG | $5.0B | — (loss-making) | — (loss-making) | +1,041.37% (above 0%: growing) | n/m | +26.19% (above 0%: growing) | 100.00% | (1,151.84%) | Compare |
| Median of peers | $5.3B | — | — | +37.92% | — | −5.31% | 41.39% | 0.00% |
CG Oncology, Inc. (CGON) key facts
- Strength: CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- CG Oncology, Inc. (CGON) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CGON traded at $59.79, a market capitalization of $5.5 billion.
- Return on equity was −21.7% and debt-to-equity 0.00.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 49.04 (safe zone) for fiscal 2025.